Industry News (Patents and Technology)

U.S. Patents for P53 and RB1 Cancer Gene Tests Received

Published in Gene Therapy Weekly, September 16th, 1996

Visible Genetics, Inc. (VGI), Toronto, Ontario, Canada, announced the issuance of two U.S. patents covering methods and test kits that permit the rapid, inexpensive detection of mutations in two genes associated with human cancers.

The first U.S. Patent covers the p53 GeneKit, which allows users to quickly and inexpensively detect possible mutations in the DNA code of the p53 gene. The second, covers the RB1 GeneKit, which allows users to search for possible mutations in the RB1 gene from a simple blood sample.

Mutations in the p53 gene are found in a wide variety of tumors, including about 70 percent of colorectal cancers, 50 percent of lung...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-09-16)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry